Swiss-based Oculis upsizes BlackRock loan facility to €106.2M for eye disease breakthroughs
Oculis has amended its loan facility with BlackRock, increasing potential access to CHF 100M. The company develops therapies for ophthalmic and neuro-ophthalmic diseases.